Dementia

Months saved with treatment as a measure of clinical meaningfulness in AD clinical trials

Understanding compensatory factors in healthy individuals with Alzheimer’s pathology

Financial hurdles facing robotic assistive technology in dementia care

The link between hearing loss and dementia: increased cognitive load

Challenges in assessing disease modification in Alzheimer’s disease clinical trials

Optimism for NK cell therapy as a future Alzheimer’s disease treatment

Efficient use of open label extension data

A benchmark for future disease-modifying therapies in Alzheimer’s disease

Importance of addressing age-related hearing loss

Applying industry standards to improve the efficiency of drug development

Testing disease modificaition with open label extension studies

Testing anti-amyloid therapies in preclinical Alzheimer’s disease

Trial of hearing rehabilitation to slow cognitive decline in patients with MCI

The need for revised outcome measures in DLB trials

Time saved with Alzheimer’s disease therapeutics

The effect of APOE4 on lipid production in glial cells